港股创新药板块全面爆发！可T+0交易的港股创新药ETF（159567）现涨3.42%，跟踪指数最新市盈率仅27倍

Group 1 - The ASCO conference opening on May 30 will see a record number of presentations from Chinese experts, catalyzing the innovative drug sector [1] - On May 27, the National Medical Products Administration approved the innovative drug Regaglitin Metformin Tablets by Heng Rui Medicine for the treatment of adult type 2 diabetes, highlighting the growing health threat of diabetes [1] - The Hong Kong innovative drug sector is experiencing a significant valuation adjustment, with the Hong Kong innovative drug index's price-to-earnings ratio dropping from 64 times on February 21 to 27 times on May 27, indicating a strong value proposition for investors [1] Group 2 - The Hong Kong innovative drug sector saw a notable increase on May 27, with key stocks such as Junshi Bioscience rising over 17%, and others like Lepu Biopharma and CSPC Pharmaceutical rising over 7%, reflecting strong market interest [1] - The Hong Kong innovative drug ETF (159567) has shown high trading activity, with an average daily trading volume of 859 million yuan over the past five trading days, indicating robust market engagement [1] - The innovative drug ETF (159992) tracks an index that includes leading companies in the innovative drug industry, benefiting from trends such as AI-driven drug development and the expansion of domestic innovative drugs into international markets [2] Group 3 - According to Everbright Securities, the investment value of the innovative drug sector lies in its technological platform advantages and global commercialization potential, driven by changing demographics and policy adjustments [2] - The innovative drug sector is positioned to meet unmet clinical needs and achieve import substitution through technological breakthroughs, thus opening new market opportunities [2] - The high added value and differentiated advantages of innovative drugs enable them to command a higher willingness to pay, especially under supportive policies and market demand [2]